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Abstract
Advanced liver cirrhosis requiring hospitalization is frequently associated with electro-
lytic disturbances, the most common finding being serum hyponatremia. The goal of 
treatment in patients with decompensated liver cirrhosis complicated with severe hypo-
natremia is to normalize the increased amount of water in the body and to improve the 
sodium concentration. Fluid restriction is recommended at 1.5 L/day to prevent sodium 
depletion in the serum, but the lack of efficacy is probably due to a poor patient com-
pliance. Discontinuation or adjustments of diuretic dosages are sometimes required. 
Albumin associated with vasoconstrictors as midodrine can increase the effective arte-
rial blood volume and seems to improve the serum sodium concentration. A promis-
ing therapeutic option targeting the pathophysiological mechanism of hyponatremia 
consists of improving solute-free water excretion, which is markedly impaired in these 
patients. The use of agents such as k opioid agonists has been attempted, but has been 
dropped due to the severe side effects. Recently, a new therapeutic class called vaptans 
has taken an important place in the treatment of hypervolemic hyponatremia. The main 
side effects during the administration of these drugs in patients with liver cirrhosis are 
reversible after discontinuing therapy. Therefore, it is recommended to use vaptans for 
short periods of time.
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1. Introduction
Ascites is the most common complication of cirrhosis, approximately 60% of patients develop 
ascites within 10 years of disease progression. The mechanism of production is the devel-
opment of portal hypertension and renal retention of sodium. This inability to excrete an 
adequate amount of sodium in the urine occurs due to arterial splanchnic vasodilatation. 
Therefore, arterial and pulmonary cardio vascular receptor activation occurs with homeo-
static activation of vasoconstrictor and sodium retention systems, resulting in a decrease in 
the required arterial blood volume. Renal sodium retention increases the volume of extracel-
lular fluid leading to ascites and edema [1–5].
At approximately 75% of patients from Western Europe and USA, the main cause of ascites is 
represented by cirrhosis. Other causes of ascites may be malignancy, heart failure, tuberculo-
sis, pancreatic disease, or other causes.
Hyponatremia is one of the complications that occurs in end stage cirrhosis due to the impos-
sibility of renal clearance of free water, which leads to a higher water retention than sodium 
with the occurrence of hyposomolarity, with an increase in mortality and morbidity. In the 
pathogenesis of hyponatremia, the main factor involved is hypersecretion of antidiuretic 
hormone (ADH). Hyponatremia is a risk factor for both hepatic encephalopathy and liver 
transplantation because it is associated with an increased frequency of complications and a 
short-term survival [6].
2. Definition
Patients with liver cirrhosis show two types of hyponatremia: hypovolemic and hypervolemic.
Hypervolemic hyponatremia is the most common form and is characterized by low levels of 
serum sodium and increased volume of extracellular fluid, ascites, and edema. It may appear 
secondary to bacterial infections, excessive hypotonic fluids or may occur spontaneously. 
Hypovolemic hyponatremia is less common, with low levels of sodium, without ascites and 
edema as a consequence of excessive diuretic administration.
Hyponatremia is defined when serum sodium levels fall below 130 mmol/L but according to 
the recent guidelines, reductions below 135 mmol/L should also be considered as hyponatre-
mia [7].
3. Prevalence
A study made over an Asian population following 997 patients with cirrhosis and ascites over 
28 days in 28 centers showed that hyponatremia is present in more than half of the patients [8].
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4. Pathophysiology
The mechanism by which ascites fluid is formed is the excess water and sodium retention in 
the body. Several theories have been developed to understand pathophysiology, and in turn, 
it has been shown that much of it would arise as a result of portal hypertension. The three 
proposed theories are three distinct mechanisms named: filling, oversaturation, and periph-
eral arterial vasodilatation. The first theory of filling is determined by portal hypertension and 
decreased circulating volume that produces vascular fluid retention. Since cirrhotic patients 
have a higher percentage of hypervolemia than hypovolemia, the second overload theory is 
determined by the retention of water and sodium in the absence of volume exhaustion. And 
the third theory uses the first two theories. This indicates that vasodilation occurs as a result 
of portal hypertension and favors the increase in arterial blood volume. Also, several factors 
are involved in ascites fluid formation: hypoalbuminemia and oncotic low plasma pressure, 
elevated levels of epinephrine and norepinephrine.
The main mechanism of hyponatremia is represented by arterial vasodilation. By reducing 
effective blood volume, several neurohumoral systems such as the renin-angiotensin-aldo-
sterone system and the sympathetic nervous system are stimulated and lead to the release of 
ADH.
Activation of those trigger systems causes sodium retention and may lead to renal vasocon-
striction. Vasopressin 2 receptors affected by the ADH play an important role in rate of excre-
tion of solute-free water. In the end, water excretion occurs with the appearance of serum 
dilution and hypo-osmolality [6].
Under normal circumstances, there is a synchronous increase in serum osmolarity and ADH 
secretion, and reabsorption of water occurs when activating the aquaporin channels in the 
renal collection tubes. In opposite, the inactivation of aquaporin channels occurs when a 
decrease in osmolarity appears, resulting in urine dilution as a mechanism in maintaining 
serum osmolarity. Thus, the good functioning of osmoreceptors in the anterior hypothala-
mus, the release of ADH and the mutual action between ADH and AQP-2 compete to adapt 
the release of free water.
ADH is secreted into the supraoptic and paraventricular nuclei of the hypothalamus and 
maintained in the posterior pituitary gland. Vasopressin secretion is stimulated by increased 
plasma osmolarity and hypovolemia. The release of ADH is conditioned by osmotic and 
nonosmotic stimulation. The osmoreceptors in the anterior hypothalamus, near the supra-
optic nuclei mediate the osmotic pathway. These receptors detect intracellular water content 
in neurons and respond to changes in plasma osmolarity. The main nonosmotic pathway 
delivers an ADH release through the autonomic nervous system mediated by baroreceptors 
located in the atrium, ventricle, aortic arch, and carotid sinus. Through the parasympathetic 
pathway, these baroreceptors stimulate the hypothalamus to release ADH in response to 
hypovolemia [9].
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Most patients with cirrhosis present low serum osmolarity and sodium levels, and it is expected 
to produce inhibition of ADH release if stimulation was achieved by osmoreceptors [10]. 
Because of the activation of the neurohumoral mechanisms that retain sodium, the levels of 
ADH, aldosterone, norepinephrine, and renin activity were significantly higher in patients 
with cirrhosis and ascites after the water loading test. Effective arterial uptake would result 
from a decrease in systemic vascular resistance and would result in nonosmotic stimulation 
due to baroreceptors of ADH and other vasoconstriction systems. These cause the activation 
of the neurohumoral mechanisms that produce sodium retention in order to restore the perfu-
sion pressure [11].
It is suggested that hypoosmotic stimuli are suppressed by nonosmotic stimuli to suppress 
ADH release. That is why the body sacrifices osmolar homeostasis and releases ADH fol-
lowing nonosmotic stimulation of endogenous vasoconstrictors, and thus impairs vascular 
collapse by exhausting effective circulatory volume. It results in an inability to release sodium 
and water to replenish the circulation volume. All of these things happen despite the increase 
in cardiac output, plasma volume, and total body volume. To eliminate the extra amount of 
water, it is necessary to suppress adherence and the ability of the kidneys to remove water. 
The presence of nonosmotic adherence leads to the occurrence of a hyponatremia of dilution 
or hypervolemic hyponatremia. Therefore, in this category of patients, hyponatremia is only 
dilute and does not represent a sodium deficiency [12].
In a prospective cohort study of patients with ascites, it was demonstrated that the occur-
rence of hyponatremia is preceded by refractory ascites and subsequently by hepatorenal syn-
drome. Each of these steps was associated with a progressive Child Pugh score and Model for 
End Stage Liver Disease (MELD) indicating a worsening of liver function. Therefore, hypona-
tremia is an intermediate stage between ascites progression and hepatorenal syndrome [13].
5. Prognostic value
Hyponatremia in patients with cirrhosis is chronic, therefore, allows the brain to adapt to 
the hypo extracellular fluid osmolality. In conclusion, patients are less likely to have severe 
neurological symptoms. However, hyponatremia can aggravate cerebral edema and swollen 
astrocytes by adding to their dysfunction created by increased intracellular glutamine con-
centration, speeding up the appearance of hepatic encephalopathy [6].
Due to the severe restriction of fluid consumption, the quality of life of patients with cirrhosis 
and hyponatremia is poor [14]. Several studies have shown that the severity of hyponatremia 
and ascites is a prognostic factor of the disease [15, 16]. In one study, it was demonstrated that 
the serum sodium level prior to the occurrence of spontaneous bacterial peritonitis (SBP) was 
an independent predictor of renal insufficiency produced by SBP [17]. It is also a predictive 
marker with a higher sensitivity than serum creatinine to predict the occurrence of circulatory 
dysfunction resulting in renal insufficiency or death. Although patients with hyponatremia 
are susceptible to the hepatorenal syndrome, there is not only an increased level of ADH 
involved, but there is a decrease in glomerular filtration rate (GFR) and proximal sodium 
reabsorption [18].
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Sodium concentration was included in the MELD model to indicate the need for liver trans-
plantation and patient priority on waiting lists in order to improve prognosis [19]. It was 
found that the MELD-Na score indicated an anticipation of short-term mortality of transplant 
patient candidates much better than the initial MELD score [20].
6. Clinical presentation
Symptoms of hyponatremia are caused by the damage to the nervous system, with cerebral 
edema due to the migration of water from the intravascular space in the brain [21]. As a rapid 
adaptive mechanism, there is an increase in electrolytes in brain cells. As a slow adaptation 
mechanism, organic osmoliths are extruded. Finally, these mechanisms help return the water 
to the intravascular space and prevent brain edema [22].
Figure 1. Clinical manifestations of hyponatremia.
Management of Ascites Associated with Severe Hyponatremia
http://dx.doi.org/10.5772/intechopen.76376
21
In patients without hepatic impairment, hyponatremia manifests with: headache, disorien-
tation, confusion, and neurological deficits. In contrast, in cirrhotic patients, hyponatremia 
develops slowly and at a value of 125 mEq/L is asymptomatic due to adaptive mechanisms. 
However, a rapid drop in sodium concentration may overcome adaptive mechanisms and 
serious symptoms may occur such as coma, seizures, brain-stern herniation, respiratory fail-
ure, and death [23] (Figure 1).
Hyponatremia usually occurs in the final stage of liver disease and is difficult to differentiate 
if the symptoms are within it or are part of liver encephalopathy occurrence. Both hyponatre-
mia and hyperammonemia cause an alteration in brain metabolism of myoinositol [24].
Some theories show that hyponatremia can cause the appearance of a minimal cerebral edema 
that occurs by swelling of astrocytes and may cause the appearance of hepatic encephalopa-
thy. This minimal brain edema occurs by increasing the concentration of glutamine resulting 
from the metabolism of ammonia and leads to a series of neurological changes to the appear-
ance of hepatic encephalopathy [25].
7. Complications
Central pontine myelinolysis (CPM) is a complication of severe hyponatremia and occurs 
when its correction has been achieved very quickly. It is a neurological disorder that consists 
of a demyelination that occurs in a region called pons [26].
The mechanism by which this affection occurs is not fully known. One theory claims that 
this demyelination occurs by compressing fibrous structures as a result of cerebral edema 
arising from an osmotic fluctuation. Currently accepted theory supports the fact that brain 
cells adjust their osmolarity with certain osmolites, like inositol, betaine, and glutamine. In 
case of chronic hyponatremia, there is a decrease in these osmoliths in the brain, preventing 
fluid absorption [27, 28]. Clinical manifestations depend on the affected brain region, initially 
manifested by symptoms of hyponatremic encephalopathy such as nausea, vomiting, head-
ache, confusion, and seizures. These symptoms can be reversed when adjusting the sodium 
concentration. Later signs of myelinolysis such as walking disturbances and respiratory 
dysfunction can occur [29]. Among the risk factors for this condition are: sodium concentra-
tion < 120 mEq/L for 48 hours, aggressive correction with saline solution and the occurrence of 
hypernatremia during treatment. If post liver transplant patients develop symptoms as confu-
sion or weakness, CPM should be suspected because it may complicate a liver transplant [30].
Although the prognosis is poor with the occurrence of numerous neurological complications 
such as spastic quadriparesis and blocked syndrome, recovery is possible although it has a 
long duration [31].
Diagnosis can be done clinically and imagistically. The preferred imaging method is MRI, 
although lesions appear late and often initially may be normal [32]. The most common images 
are T2 weighted with hyperintense areas where demyelination was performed [33].
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8. Management of hyponatremia
There are no data to recommend optimal serum sodium to initiate the treatment, but is gener-
ally recommended at a value of 130 mmol/L.
The identification and adjustment of excessive diuretic dosages and the addition of sodium 
are the main treatment requirements in the setting of hypovolemic hyponatremia. In case of 
hypervolemic hyponatremia, the most important issue is to decrease the amount of water to 
improve the sodium concentration.
When patients experience neurological symptoms due to hyponatremia or have a sodium 
concentration of less than 120 mEq/L, fluid restriction is indicated. In the case of mild and 
asymptomatic hyponatremia, fluid restriction is not indicated. Increasing sodium concentra-
tion in the first 24–48 hours is an important parameter that suggests an adequate fluid restric-
tion. If this increase does not occur, either the restriction has to be more severe or the patient is 
not compliant. Fluid restriction is useful, but ineffective. Because the fluid restriction is severe, 
most patients cannot be compliant.
If patients have severe hyponatremia, there have been no responses to fluid restriction; it is 
indicated to administer the hypertonic saline. However, caution should be exercised in order 
not to cause a rapid increase in sodium concentration, which predisposes to the occurrence 
of numerous complications such as: central myelinolysis, quadriplegia, coma, or death [6].
The efficacy of using hypertonic sodium chloride in severe hypervolemic hyponatremia 
is partial, short-lived and aggravates ascites and edema. Instead, administration of albu-
min appears to have benefits, helps to increase the sodium concentration, but is not fully 
studied [34].
An important issue in patients with cirrhosis and hyponatremia is the correction of hypokale-
mia. Hypokalemia favors the appearance of hepatic encephalopathy because it increases the 
kidney synthesis of ammonium. By correcting it, there is also an increase in sodium concen-
tration because both sodium and potassium are osmotically active [35].
In the past, the use of k-opiod agonist therapy has been attempted due to side effects [36]. 
According to recent studies, a new class of therapy, called vaptans, has been discovered in 
the treatment of hypervolemic hyponatremia. Vaptans selectively block the V2-receptors 
of AVP. They can be used in diseases like syndrome of inappropriate antidiuretic hormone 
secretion (SIADH), heart failure and cirrhosis, having the role of improving sodium concen-
tration. The benefits of their administration over a short period of time are the increasing of 
urine volume and solute-free water excretion, and also, the improvement of the low serum 
sodium levels in 45–82% of patients [37] (Figure 2).
Hypernatremia, dehydration, renal impairment, and osmotic demyelination syndrome owing 
to a very rapid increase in serum sodium concentration could be the side effects of the admin-
istration of vaptans in patients with liver cirrhosis. Therefore, treatment should be initiated in 
the hospital and patients should be closely monitored to avoid hypernatremia.
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Due to the risk of dehydration and hypernatremia, vaptans are also contraindicated in patients 
with an inappropriate consciousness state, unable to measure the volumes of fluid consumed.
The metabolism of vaptans is achieved in the liver by CYP3A enzymes. Therefore, CYP3A 
inhibitory drugs should be avoided because they increase the concentration of vaptans and 
may lead to the increase of serum sodium concentration. Also, drugs that are inducers of the 
CYP3A should be avoided because those drugs can reduce the concentration of vaptans.
Figure 2. Management of hyponatremia.
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Tolvaptan and conivaptan are recently approved in the USA for the treatment of 
severe hypervolemic hyponatremia from diseases such as cirrhosis, heart failure and 
SIADH. Treatment is started at a dose of 15 mg/day and can be increased progressively 
depending on the sodium concentration. In Europe, tolvaptan is authorized only for the 
treatment of SIADH. As an alternative option, conivaptan can be used to treat hypervolemic 
hyponatremia for short periods of time, especially when cirrhosis is associated with various 
conditions [38, 39].
Tolvaptan should be initiated without taking into account the period of meals, but initially 
it is advisable not to suppress the consumption of fluids to avoid rapid correction of sodium 
concentration. If, on completion of tolvaptan therapy, hyponatremia recurs, it should be cor-
rected in a hospital unit. There may be no need for hospitalization, if treatment can be moni-
tored to prevent excessive sodium concentration [40].
In randomized trials, the only side effects of tolvaptan treatment were gastrointestinal bleed-
ing, but slightly increased incidence compared to placebo. It should be taken into account that 
the treatment was administered over a short period of time and new studies of the safety of 
long-term treatment are needed [41].
Treatment with conivaptan is contraindicated in patients who are allergic to constituents, in 
hyponatremia or hypovolaemia because it can induce from renal failure to shock. CYP3a4 
inhibitors should not be administered concomitantly [42]. In general, the treatment was 
tolerated and adverse reactions were reported: local reactions (pain and erythema at the 
administration level), orthostatic hypotension, peripheral edema, headache, nausea, vomit-
ing, urinary tract infections, and insomnia [43]. Effective treatment of hyponatremia should 
be initiated promptly to prevent irreversible neurological damage, but rapid correction may 
cause osmotic demyelination syndrome that can lead to death [44].
Domecycline favors the increase in free water excretion as an ADH antagonist, but cannot be 
used in cirrhosis due to nephrotoxicity [45].
The use of vasoconstrictors in hyponatremia is not tested, but studies of the hepatorenal syn-
drome have shown an improvement in sodium concentration [46].
The use of vasoconstrictors in hepatorenal syndrome has the following benefits: it improves 
the effective blood volume, vascular or systemic vasodilation, and renal perfusion. They are 
usually used in concomitant albumin administration. The most commonly used are: terlipres-
sin, norepinephrine, vasopressin, and octeotrid, in combination with midodrine.
This combination can be used without supervision in a medical unit and is safe. Octreotide 
produces decreased splanchnic vasodilatation and midodrine improves renal perfusion and 
in combination with albumin improves kidney function, but there are still insufficient studies 
in this regard.
The octreotide is administered subcutaneously at the dose of 100 micrograms, 3 times per 
day, and the dose can be increased to 200 μg, 3 times per day. Midodrine is given orally 
7.5 mg, 3 times per day and the dose can also be increased up to 12.5 mg, 3 times per day [47].
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Treatment with terlipressin should be avoided in patients with cirrhosis, as it may cause severe 
hyponatremia, reversible upon discontinuation of treatment. Terlipresin acts on the vasopres-
sin V1 receptor, but is also a partial vasopressin V2 receptor agonist. This is beneficial in the 
treatment of bleeding caused by portal hypertension, but also in hepatorenal syndrome [48].
By correcting hyponatremia in patients with cirrhosis, there are number of advantages: avoid-
ing fluid restriction, administering effective doses of diuretics, especially in the treatment of 
refractory ascites, reducing the risk by developing hepatic encephalopathy, and improving the 
quality of life. It can also help reduce neurological complications after transplantation [49, 50].
9. Conclusions
Hyponatremia is a complication of cirrhosis, associated with an increased risk of mortality 
and morbidity in patients on the waiting list for a liver transplant. It also increases the risk 
of complications, such as hepatic encephalopathy, renal failure, and spontaneous bacterial 
peritonitis.
Hyponatremia occurred during cirrhosis evolution has as a pathophysiological mechanism 
arterial vasodilation that produces inadequate AVP secretion and a reduction in glomerular fil-
tration rate with impairment of free water clearance. Clinical presentation does not differ from 
that of patients without hepatic impairment, but the symptoms of hyponatremia in cirrhosis 
are sometimes associated and difficult to differentiate from those in hepatic encephalopathy. 
As a dilutional hyponatremia, its treatment is not indicated if it is asymptomatic. Conversely, 
at a concentration of Na <120 mEq/L and on the occurrence of neurological symptoms, treat-
ment can be initiated. An exception is the situation where patients are about to receive a liver 
transplant in a short time and the Na concentration is <130 mEq/L. In this case, its treatment 
is indicated to prevent the occurrence of serious neurological complications such as osmotic 
demyelination syndrome as a result of a rapid correction in the operating room. An important 
role is the differentiation of hypovolemic hyponatremia from the hypervolemic hyponatre-
mia to initiate a suitable therapeutic scheme. In hypovolemic hyponatremia, it is necessary to 
identify the trigger factor and its treatment, usually discontinuation of diuretic treatment and 
administration of salt solution represents optimal methods in the correction of this. In hyper-
volemic hyponatremia, therapeutic methods are limited. Fluid restriction to about 1 L/day is 
important in improving Na concentration, but a small number of patients may be compliant 
with this therapy. Administration of saline solution in this case is only recommended if hypona-
tremia is severe because it usually favors the growth of ascites fluid and edema. Administration 
of albumin appears to be beneficial, but there is not enough data to confirm this.
A novelty in hyponatremic therapy is the treatment with vaptans. Treatment with tolvaptan 
should be given in the hospital to avoid a sudden increase in Na concentration, in oral admin-
istration, and with the possibility to increase the dose progressively to achieve the desired 
effects. Concomitant administration with vaptans of saline solution or fluid restriction is 
contraindicated to prevent osmotic demyelination syndrome. Medications that are inhibi-
tors or inducers of CYP3A are also contraindicated. Conivaptan is given intravenously. Both 
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conivaptan and tolvaptan can be administered for a short period of time, and hyponatremia 
may reappear when the treatment is stopped. Although treatment with vaptans is effective in 
relieving hyponatremia, their use requires additional data.
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